ImMoRiSt
Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ImMoRiSt project word cloud
Explore the words cloud of the ImMoRiSt project. It provides you a very rough idea of what is the project "ImMoRiSt" about.
Project "ImMoRiSt" data sheet
The following table provides information about the project.
| Coordinator |
LOPHIUS BIOSCIENCES GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-02-01 to 2016-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | LOPHIUS BIOSCIENCES GMBH | DE (REGENSBURG) | coordinator | 50˙000.00 |
Map
Project objective
Every year ~ 40.000 patients throughout the EU are transplanted a new kidney, lung, liver, heart or another organ. The frequency of clinical complications is relatively high because at present there are no diagnostic tests that help physicians to determine the right dosage of immunosuppressive drugs necessary to avoid both organ rejection and clinical complications caused by infections.
Lophius Biosciences GmbH has developed I-Scan, a functional immune monitoring test that within 24 h provides important information on the strength of the immune system in solid organ transplant recipients. I-Scan uses a proprietary cocktail of stimulants that selectively stimulate the clinically relevant immune cells in a patient’s blood sample. The detection of the triggered interferon γ (IFN-γ) release provides a qualitative and quantitative measurement of cell-mediated immune function.
The feasibility study performed during Phase 1 will explore issues related to both, the clinical biomarker validation study and the best market entry strategy. Several objectives are pursued in parallel and encompass: • Setting up the business plan which includes a competitor as well as a freedom-to-operate analysis and a market entry strategy. • Selection of clinical study partners and defining the design of the clinical study, best suited to yield highest clinical evidence • Obtaining regulatory approval for the planned clinical study and setting a strategy to obtain regulatory approval / CE-Marking for final I-Scan products.
Lophius will apply for Phase 2 funding of a clinical study to validate that I-Scan improves the outcome of SOT patients. This study is likely to take place in Germany, Switzerland and Austria where Lophius has already established firm links to transplantation centers. The study is the logical next step to further grow Lophius to become a global leader in the IVD market for immunomonitoring
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORIST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMORIST" are provided by the European Opendata Portal: CORDIS opendata.